Edwards Lifesciences Co. (NYSE:EW) Stock Position Raised by Guinness Asset Management LTD

Guinness Asset Management LTD raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 45.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,798 shares of the medical research company’s stock after purchasing an additional 2,737 shares during the period. Guinness Asset Management LTD’s holdings in Edwards Lifesciences were worth $581,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. Perfromance Wealth Partners LLC raised its stake in shares of Edwards Lifesciences by 5.8% in the 3rd quarter. Perfromance Wealth Partners LLC now owns 4,512 shares of the medical research company’s stock valued at $298,000 after acquiring an additional 248 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Edwards Lifesciences by 47.5% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 24,837 shares of the medical research company’s stock valued at $1,639,000 after acquiring an additional 8,000 shares in the last quarter. West Coast Financial LLC raised its stake in shares of Edwards Lifesciences by 0.6% in the 3rd quarter. West Coast Financial LLC now owns 143,213 shares of the medical research company’s stock valued at $9,451,000 after acquiring an additional 874 shares in the last quarter. Boston Common Asset Management LLC raised its stake in shares of Edwards Lifesciences by 4.0% in the 3rd quarter. Boston Common Asset Management LLC now owns 207,924 shares of the medical research company’s stock valued at $13,721,000 after acquiring an additional 7,973 shares in the last quarter. Finally, Capital Insight Partners LLC raised its stake in shares of Edwards Lifesciences by 7.7% in the 3rd quarter. Capital Insight Partners LLC now owns 60,328 shares of the medical research company’s stock valued at $3,981,000 after acquiring an additional 4,290 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on EW shares. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $105.00 to $72.00 in a report on Thursday, July 25th. Citigroup lowered their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a report on Tuesday, October 1st. Barclays lowered their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Finally, Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Seventeen analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $75.77.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,250 shares of company stock worth $751,688. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $0.13 during midday trading on Friday, hitting $68.13. 4,185,884 shares of the company were exchanged, compared to its average volume of 4,575,058. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The firm has a market cap of $41.04 billion, a P/E ratio of 28.04, a PEG ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a 50 day simple moving average of $67.13 and a 200-day simple moving average of $80.17.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the company earned $0.66 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.